Years later after 2010, Dendreon has unveiled new data showing the med generates a killer T-cell response—and the strength of that response correlates with overall survival.
A year after NewLink Genetics reported a phase 3 trial failure for its pancreatic cancer vaccine that crushed shares, a shareholder is taking it to the company’s current and former execs for “gross mismanagement” and other allegations.